280 related articles for article (PubMed ID: 29057233)
1. Relevance of genetic alterations in squamous and small cell lung cancer.
Sabari JK; Paik PK
Ann Transl Med; 2017 Sep; 5(18):373. PubMed ID: 29057233
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.
Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J
Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519
[TBL] [Abstract][Full Text] [Related]
3. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
Front Oncol; 2014; 4():58. PubMed ID: 24744988
[TBL] [Abstract][Full Text] [Related]
4. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Arbour KC; Riely GJ
JAMA; 2019 Aug; 322(8):764-774. PubMed ID: 31454018
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
6. Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in
Shaurova T; Zhang L; Goodrich DW; Hershberger PA
Front Genet; 2020; 11():281. PubMed ID: 32292420
[TBL] [Abstract][Full Text] [Related]
7. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
8. New Treatment Options in Advanced Squamous Cell Lung Cancer.
Paik PK; Pillai RN; Lathan CS; Velasco SA; Papadimitrakopoulou V
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e198-e206. PubMed ID: 31099625
[TBL] [Abstract][Full Text] [Related]
9. [Advances of molecular targeted therapy in squamous cell lung cancer].
Ma L; Zhang S
Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):671-5. PubMed ID: 24345494
[TBL] [Abstract][Full Text] [Related]
10. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
Goss GD; Spaans JN
Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
[TBL] [Abstract][Full Text] [Related]
11. Cancer genomics of lung cancer including malignant mesothelioma: A brief overview of current status and future prospects.
Jhanwar SC; Xu XL; Elahi AH; Abramson DH
Adv Biol Regul; 2020 Dec; 78():100723. PubMed ID: 32992231
[TBL] [Abstract][Full Text] [Related]
12. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Tsironis G; Ziogas DC; Kyriazoglou A; Lykka M; Koutsoukos K; Bamias A; Dimopoulos MA
Ann Transl Med; 2018 Apr; 6(8):143. PubMed ID: 29862232
[TBL] [Abstract][Full Text] [Related]
13. [Progress on the Study of Targeting FGFR in Squamous Non-small Cell Lung Cancer].
Dong M; Li T; Chen J
Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):116-120. PubMed ID: 29526179
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges.
Mielgo-Rubio X; Martín M; Remon J; Higuera O; Calvo V; Jarabo JR; Conde E; Luna J; Provencio M; De Castro J; López-Ríos F; Hernando-Trancho F; Couñago F
Future Oncol; 2021 Oct; 17(30):4011-4025. PubMed ID: 34337973
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of Advanced Squamous Cell Lung Cancer].
Zhu Y; Xing P; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):687-691. PubMed ID: 27760600
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract][Full Text] [Related]
17. Emerging Biomarkers and the Changing Landscape of Small Cell Lung Cancer.
Keogh A; Finn S; Radonic T
Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954436
[TBL] [Abstract][Full Text] [Related]
18. Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
Friedlaender A; Banna G; Malapelle U; Pisapia P; Addeo A
Front Oncol; 2019; 9():166. PubMed ID: 30941314
[TBL] [Abstract][Full Text] [Related]
19. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
20. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
Halliday PR; Blakely CM; Bivona TG
Curr Oncol Rep; 2019 Feb; 21(3):21. PubMed ID: 30806814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
